Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
TPC induction chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
TPIV200
Marker Therapeutics
Ovarian Cancer
1 trial -
TPX-0005-07
Turn Therapeutics
Advanced solid tumors
1 trial -
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Prostatic Neoplasms, Castration-Resistant
1 trial -
TQB3616 capsules
Chia Tai Tianqing Pharmaceutical Group Co.,
HR-positive, HER2-negative Advanced Breast Cancer
1 trial -
TRAP-BTC
The George Institute
cholangiocarcinoma or gallbladder carcinoma
1 trial -
TRASTUZUMAB DERUXTECAN
Fondazione Telethon ETS
metastatic HER2-positive breast cancer patients
1 trial -
TRASTUZUMAB DERUXTECAN, SACITUZUMAB GOVITECAN
Ningbo Cancer Hospital
Patients with metastatic or locally advanced HER2-low triple-negative breast cancer and eligible to receive sacituzumab-govitecan and T-Dxd according to their indication.
1 trial -
TRC105
United Therapeutics Europe Ltd
Metastatic Breast Cancer
1 trial -
TREMELIMUMAB for locally advanced cholangiocarcinoma
Fondazione Telethon ETS
locally advanced cholangiocarcinoma
1 trial -
TREMELIMUMAB, DURVALUMAB
The George Institute
MSS and MSI colorectal and endometrial tumors
1 trial -
TRU-016 and bendamustine
Aptevo Therapeutics
Chronic Lymphocytic Leukemia (CLL)
1 trial -
TS-1 with cisplatin
Hospital Authority, Hong Kong
Recurrent Gastric Cancer
1 trial -
TTI-101
Tvardi Therapeutics
Head and Neck Squamous Cell Carcinoma
1 trial -
TTI-101
Tvardi Therapeutics
Hepatocellular Carcinoma
1 trial -
TTX-MC138
Transcode Therapeutics
Advanced Solid Tumor
1 trial -
TYR300-101
Tyra Biosciences
Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations
1 trial -
TYR300-202
Tyra Biosciences
Non-muscle invasive bladder cancer (NMIBC)
1 trial -
TYRA-300
Tyra Biosciences
Locally Advanced Urothelial Carcinoma
1 trial -
Tabelecleucel
Evidence Based Cataract Study Group
Nasopharyngeal Carcinoma
1 trial -
Tagraxofusp
Stemline Therapeutics B.V.
Acute Myeloid Leukemia
1 trial -
Tak-228 & Tak-117
Takeda
Triple Negative Breast Cancer
1 trial -
Talazoparib Tosylate
BioMarin Pharmaceutical Australia Pty Ltd
Advanced Breast Cancer
1 trial -
Tarlatamab
Amgen
Relapsed/Refractory Small Cell Lung Cancer
1 trial -
Tarlatamab, Tarlatamab
The George Institute
Metastaic small cell lung cancer (SCLC) and other poorly differentitated neuroendocrine carcinomas (NECs)
1 trial -
Tarlatamab, Tarlatamab
Partner Therapeutics Limited
Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2
1 trial -
Tas-102(Suyuan) combined with bevacizumab
The First People's Hospital of Lianyungang
Colorectal Cancer
1 trial -
Taxotere
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Tazemetostat
Eisai Co.,
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Wuhan Createrna Science and Technology Co., Ltd
Limited disease small-cell lung cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
The George Institute
Locally advanced cervical cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Tour Hekla
Muscle-invasive bladder cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Ningbo Cancer Hospital
Muscle-invasive bladder cancer
1 trial -
Tecentriq 1 200 mg concentrate for solution for infusion
Disc Medicine
(Diffuse) Large B-cell Lymphoma
1 trial -
Tecentriq 840 mg concentrate for solution for infusion
Hoffmann-La Roche
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Tegafur Gimeracil Oteracil Potassium Capsule
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer
1 trial -
Telehealth Intervention
United Therapeutics Europe Ltd
Colorectal Cancer
1 trial -
Telisotuzumab Vedotin
AbbVie Deutschland GmbH & Co. KG
Non-Small Cell Lung Cancer
1 trial -
Telisotuzumab adizutecan
AbbVie Deutschland GmbH & Co. KG
Colorectal Cancer
1 trial -
Temsirolimus
PUMA BIOTECHNOLOGY, INC.
Breast Cancer
1 trial -
Teniposide administration
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
1 trial -
Tepotinib
Merck Sharp and Dohme
Lung Cancer
1 trial -
Tepotinib
Serono Europe Limited
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
1 trial -
Testosterone Enanthate 100 MG/ML Injectable Solution
Hospital Authority, Hong Kong
Castration-resistant Prostate Cancer
1 trial -
Testosterone cypionate
United Therapeutics Europe Ltd
Castration Resistant Metastatic Prostate Cancer
1 trial -
Teverelix TFA
Nordic Bioscience A/S
Advanced prostate cancer
1 trial -
Tevimbra 100 mg concentrate for solution for infusion
Ningbo Cancer Hospital
Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.
1 trial -
Thalidomide and methotrexate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
T-LGL Leukemia
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.